Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain

Non-cardiac chest pain (NCCP) in the absence of musculoskeletal abnormalities, major esophageal motor disorders, gastroesophageal reflux or eosinophilic esophagitis is called functional chest pain (FCP). Most likely multiple factors play a role, such as esophageal hypersensitivity and enhanced perception. Citalopram and other antidepressants are proven to be effective in the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. With this trial the investigators want to assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.

Inclusion Criteria:Written informed consentMinimum age: 18 yearsFunctional chest pain according to Rome IV criteriaRuled out cardiac origin of chest painECG with corrected QT interval (QTc) within the normal range (<450ms male, <460ms female)Symptoms of chest pain for at least 6 monthsFrequency of symptoms at least once a weekGastroduodenoscopy, high-resolution manometry and 24-hour pH-impedance monitoring need to have been performed recently.Exclusion Criteria:Currently using antidepressantsContraindication for the use of SSRIAlready tried antidepressants off-label to treat chest painKnown allergy to citalopramSevere and clinically unstable concomitant diseasePregnant, lactating or fertile women (without contraception)